Neoadjuvant chemotherapy combined with interval cytoreductive surgery in ovarian cancer.
This study aimed to explore the value and prognosis-influencing factors for neoadjuvant chemotherapy combined with interval cytoreductive surgery in patients with advanced ovarian cancer. 178 patients were divided into the research group and control group. The research group was treated with neoadjuvant chemotherapy combined with interval cytoreductive surgery, while the control group underwent primary cytoreductive surgery alone. Postoperative situation, efficacy, progression-free survival (PFS) and overall survival (OS) were compared between the two groups of patients, and the postoperative influencing factors for the patients were analyzed. The operation time, intraoperative blood loss and ascites volume in patients in the research group were shorter and lower than those in the control group (p<0.05). Univariate Cox regression analysis showed that the size of residual lesions after cytoreductive surgery, age, the International Federation of Gynecology and Obstetrics (FIGO) stage, the maximum primary tumor diameter and results of ascites cytological examination were the influencing factors for the OS of patients in the research group. The size of residual lesions after cytoreductive surgery, age and FIGO stage were independent factors affecting the postoperative OS of patients in the research group. Administering neoadjuvant chemotherapy combined with interval cytoreductive surgery for patients with advanced ovarian cancer can reduce the operation time, intraoperative blood loss and ascites volume. Besides, the size of residual lesions after cytoreductive surgery, age and FIGO stage are independent factors affecting the postoperative OS of patients.